Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

@article{Jain2015OutcomesOP,
  title={Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.},
  author={Preetesh Jain and Michael J Keating and William G Wierda and Zeev Estrov and Alessandra Ferrajoli and Nitin Jain and Binsah George and Danelle Frances James and Hagop M Kantarjian and Jan A Burger and Susan M O'Brien},
  journal={Blood},
  year={2015},
  volume={125 13},
  pages={2062-7}
}
Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-seven patients were enrolled in various clinical trials of ibrutinib, with or without rituximab, at our center. Thirty-three (26%) patients have discontinued ibrutinib to date. The majority of those… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 23 times over the past 90 days. VIEW TWEETS
70 Citations
9 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

References

Publications referenced by this paper.
Showing 1-9 of 9 references

Independent evaluation of ibrutinib efficacy 3 years postinitiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease

  • S O’Brien, S Coutre, I Flinn
  • J Clin Oncol
  • 2014
2 Excerpts

Similar Papers

Loading similar papers…